PAM
BMY.RT

Peak Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Peak Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,455
Closed -$8K – 158
2020
Q4 		$8K Hold
11,455
– – ﹤0.01% 148
2020
Q3 		$26K Hold
11,455
– – 0.01% 135
2020
Q2 		$41K Hold
11,455
– – 0.01% 123
2020
Q1 		$44K Buy
+11,455
New +$37.7K 0.02% 112

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Peak Asset Management's BMY.RT Position: Q1 2021 in Review

Peak Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 11,455 shares — an estimated $8K sold.

Peak Asset Management first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $44K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Peak Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Peak Asset Management sold 11,455 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $8K.
  • Peak Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Peak Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $44K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Peak Asset Management's 13F filing for Q1 2021, filed 13 May 2021.